Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of moderate to severe active ulcerative colitis (UC) in adults.
Etrasimod: Precautions and Monitoring for Medication Use
Contraindications
Patients who have experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack (TIA), or decompensated heart failure requiring hospitalization within the past 6 months.
Patients with Mobitz Type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sinoatrial block (unless the patient has a functional pacemaker implanted).
Requirements for Baseline Assessment
Blood Tests: Obtain a complete blood count (including lymphocyte count) within 6 months (or after discontinuing previous UC treatment).
Cardiac Assessment: Perform an electrocardiogram to identify potential conduction abnormalities; consultation with a cardiologist is required for specific patients.
Liver Function Tests: Obtain transaminase and bilirubin levels within 6 months.
Ophthalmic Examination: Conduct a baseline fundus examination (including macular assessment).
Skin Examination: Perform a skin examination before or shortly after the start of treatment.
Special Risk Management
Infection Risk: Opportunistic infections such as herpes zoster and cryptococcal meningitis may occur during treatment.
Cardiac Effects: The first dose may cause a transient decrease in heart rate (an average reduction of 7.2 beats per minute) and atrioventricular conduction delay.
Abnormal Liver Function: Approximately 4.5% of patients experience an increase in alanine transaminase (ALT) to more than 3 times the upper limit of normal.
Macular Edema: Regular fundus examinations are required, especially when visual changes occur.
Elevated Blood Pressure: An average increase in systolic blood pressure of 1-4 mmHg may occur; regular monitoring is necessary.
Medication Monitoring for Etrasimod
Routine Monitoring
Blood Monitoring: Regularly measure lymphocyte count during treatment.
Cardiac Monitoring: Closely monitor changes in heart rate 2-3 hours after the first dose.
Liver Function Monitoring: Immediately test liver enzymes if symptoms such as nausea or jaundice appear.
Visual Monitoring: Conduct regular ophthalmic examinations during treatment to monitor macular changes.
Monitoring in Special Populations
Hepatic Impairment: Use is not recommended in patients with severe hepatic impairment (Child-Pugh Class C).
Poor CYP2C9 Metabolizers: Concomitant use with moderate to strong inhibitors of CYP2C8 or CYP3A4 should be avoided.
Self-Monitoring
Instruct patients to recognize and report promptly:
Symptoms of infection (e.g., fever, fatigue).
Abnormal heart rate (e.g., palpitations, syncope).
Visual changes or new skin lesions.
Dyspnea or neurological symptoms.
